IBDEI0BG ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5174,1,4,0)
 ;;=4^N39.41
 ;;^UTILITY(U,$J,358.3,5174,2)
 ;;=^5015680
 ;;^UTILITY(U,$J,358.3,5175,0)
 ;;=N13.8^^27^332^21
 ;;^UTILITY(U,$J,358.3,5175,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5175,1,3,0)
 ;;=3^Urinary Obstruction
 ;;^UTILITY(U,$J,358.3,5175,1,4,0)
 ;;=4^N13.8
 ;;^UTILITY(U,$J,358.3,5175,2)
 ;;=^5015588
 ;;^UTILITY(U,$J,358.3,5176,0)
 ;;=R33.8^^27^332^22
 ;;^UTILITY(U,$J,358.3,5176,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5176,1,3,0)
 ;;=3^Urinary Retention,Unspec
 ;;^UTILITY(U,$J,358.3,5176,1,4,0)
 ;;=4^R33.8
 ;;^UTILITY(U,$J,358.3,5176,2)
 ;;=^5019331
 ;;^UTILITY(U,$J,358.3,5177,0)
 ;;=R39.15^^27^332^24
 ;;^UTILITY(U,$J,358.3,5177,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5177,1,3,0)
 ;;=3^Urinary Urgency
 ;;^UTILITY(U,$J,358.3,5177,1,4,0)
 ;;=4^R39.15
 ;;^UTILITY(U,$J,358.3,5177,2)
 ;;=^5019345
 ;;^UTILITY(U,$J,358.3,5178,0)
 ;;=R39.12^^27^332^25
 ;;^UTILITY(U,$J,358.3,5178,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5178,1,3,0)
 ;;=3^Weak Urinary Stream
 ;;^UTILITY(U,$J,358.3,5178,1,4,0)
 ;;=4^R39.12
 ;;^UTILITY(U,$J,358.3,5178,2)
 ;;=^5019342
 ;;^UTILITY(U,$J,358.3,5179,0)
 ;;=R80.9^^27^332^16
 ;;^UTILITY(U,$J,358.3,5179,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5179,1,3,0)
 ;;=3^Proteinuria,Unspec
 ;;^UTILITY(U,$J,358.3,5179,1,4,0)
 ;;=4^R80.9
 ;;^UTILITY(U,$J,358.3,5179,2)
 ;;=^5019599
 ;;^UTILITY(U,$J,358.3,5180,0)
 ;;=D51.8^^27^333^2
 ;;^UTILITY(U,$J,358.3,5180,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5180,1,3,0)
 ;;=3^Anemia,Vitamin B12 Deficiency
 ;;^UTILITY(U,$J,358.3,5180,1,4,0)
 ;;=4^D51.8
 ;;^UTILITY(U,$J,358.3,5180,2)
 ;;=^5002288
 ;;^UTILITY(U,$J,358.3,5181,0)
 ;;=D52.9^^27^333^1
 ;;^UTILITY(U,$J,358.3,5181,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5181,1,3,0)
 ;;=3^Anemia,Folate Deficiency
 ;;^UTILITY(U,$J,358.3,5181,1,4,0)
 ;;=4^D52.9
 ;;^UTILITY(U,$J,358.3,5181,2)
 ;;=^5002293
 ;;^UTILITY(U,$J,358.3,5182,0)
 ;;=I10.^^27^334^12
 ;;^UTILITY(U,$J,358.3,5182,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5182,1,3,0)
 ;;=3^Hypertension,Essential
 ;;^UTILITY(U,$J,358.3,5182,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,5182,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,5183,0)
 ;;=I15.0^^27^334^13
 ;;^UTILITY(U,$J,358.3,5183,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5183,1,3,0)
 ;;=3^Hypertension,Renovascular
 ;;^UTILITY(U,$J,358.3,5183,1,4,0)
 ;;=4^I15.0
 ;;^UTILITY(U,$J,358.3,5183,2)
 ;;=^5007071
 ;;^UTILITY(U,$J,358.3,5184,0)
 ;;=I13.11^^27^334^8
 ;;^UTILITY(U,$J,358.3,5184,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5184,1,3,0)
 ;;=3^HTN Hrt & CKD w/o Hrt Failure w/ Stage 5 Chr Kidney/ESRD
 ;;^UTILITY(U,$J,358.3,5184,1,4,0)
 ;;=4^I13.11
 ;;^UTILITY(U,$J,358.3,5184,2)
 ;;=^5007069
 ;;^UTILITY(U,$J,358.3,5185,0)
 ;;=I13.2^^27^334^7
 ;;^UTILITY(U,$J,358.3,5185,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5185,1,3,0)
 ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 5 Chr Kidney/ESRD
 ;;^UTILITY(U,$J,358.3,5185,1,4,0)
 ;;=4^I13.2
 ;;^UTILITY(U,$J,358.3,5185,2)
 ;;=^5007070
 ;;^UTILITY(U,$J,358.3,5186,0)
 ;;=I70.1^^27^334^3
 ;;^UTILITY(U,$J,358.3,5186,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5186,1,3,0)
 ;;=3^Atherosclerosis of Renal Artery
 ;;^UTILITY(U,$J,358.3,5186,1,4,0)
 ;;=4^I70.1
 ;;^UTILITY(U,$J,358.3,5186,2)
 ;;=^269760
 ;;^UTILITY(U,$J,358.3,5187,0)
 ;;=I77.3^^27^334^2
 ;;^UTILITY(U,$J,358.3,5187,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5187,1,3,0)
 ;;=3^Arterial Fibromuscular Dysplasia
 ;;^UTILITY(U,$J,358.3,5187,1,4,0)
 ;;=4^I77.3
 ;;^UTILITY(U,$J,358.3,5187,2)
 ;;=^5007812
 ;;^UTILITY(U,$J,358.3,5188,0)
 ;;=E26.02^^27^334^5
